Lantern Pharma (NASDAQ: LTRN) has secured regulatory and Institutional Review Board approvals in Taiwan to open Part 2 of its Phase 2 HARMONIC trial of LP-300, a significant step for the AI-driven precision oncology company. The lead Taiwan site is now open to accrual and actively screening patients, with two additional sites anticipated to receive IRB approval in the fourth quarter. In the United States, a central IRB has approved the amended protocol, and clinical sites have begun identifying patients with the EGFR exon 21 L858R mutation.
The trial's Part 2 will enroll patients with the L858R mutation who have progressed after tyrosine kinase inhibitor treatment. Notably, the protocol allows LP-300 to be administered for up to eight cycles in combination with carboplatin and pemetrexed, up from six cycles previously. This expansion could provide patients with more sustained treatment, potentially improving outcomes in a difficult-to-treat population.
Preliminary data from the trial showed median progression-free survival of 8.9 months among nine L858R patients who completed six cycles, compared with 8.3 months among all 16 L858R patients evaluated. While the company cautions that these findings are preliminary, exploratory, and based on small patient numbers, the results suggest a potential benefit for this biomarker-defined subgroup. The HARMONIC trial is a key part of Lantern's strategy to use its RADR artificial intelligence platform to identify patients most likely to respond to its therapies.
For investors, the Taiwan approval represents a tangible milestone that could accelerate enrollment and diversify the trial's patient pool. It also validates Lantern's biomarker-driven approach, which aims to transform the cost, pace, and precision of oncology drug development. The news comes as the company continues to advance its pipeline, which includes LP-184, LP-284, and its CNS-focused subsidiary, Starlight Therapeutics. For more details, see the full press release at https://ibn.fm/CqeDR.
Lantern Pharma's proprietary RADR platform integrates large-scale genomic and biological data with advanced machine learning to guide clinical development. The company's approach is particularly relevant in non-small cell lung cancer, where EGFR mutations drive tumor growth and treatment resistance remains a challenge. The HARMONIC trial's focus on the L858R mutation, which is the second most common EGFR mutation, addresses a significant unmet need.
The Taiwan sites will contribute to the global effort to evaluate LP-300 in this setting. With the lead site already screening patients, Lantern is positioned to generate additional data that could support future regulatory submissions. The company's newsroom, available at https://ibn.fm/LTRN, provides ongoing updates on LTRN's progress.
BioMedWire, a specialized communications platform for the biotech and life sciences sectors, originally distributed this announcement. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which offers access to a vast network of wire solutions via InvestorWire and editorial syndication to 5,000+ outlets. The platform also provides press release enhancement and social media distribution to maximize reach. For more information, visit BioMedWire.
